The number and generative capacity of human B lymphocyte progenitors, measured in vitro and in vivo, is higher in umbilical cord blood than in adult or pediatric bone marrow 
The most successful murine strains used to date are the beige/nude/XID (bnx) and the NOD/LtSz-scid/scid (NOD/ scid). There are several differences in the two xenograft systems, including the mutations responsible for the murine immunodeficiencies, the duration of the engraftment assays that can be done, and the human hematopoietic lineages that develop. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The current report focuses on differences in development of human B lymphocytes from transplanted human hematopoietic stem and progenitor cells obtained from bone marrow vs umbilical cord blood, in the bnx/hu xenograft system. Reconstitution of the B lymphoid compartment after bone marrow transplantation can lag behind recovery of other hematopoietic lineages. [14] [15] [16] Our studies indicate that human hematopoietic progenitors capable of reconstituting the B lymphocyte compartment in a xenogeneic transplant model (human to mouse) are scarce in human bone marrow, but comprise a higher percentage of human umbilical cord blood progenitors.
We established a successful xenograft system using beige/nude/xid (bnx) mice as recipients of human CD34 + hematopoietic progenitor cells that have been cultured for 72 h to allow transduction by retroviral vectors. Long-term hematopoiesis (up to 18 months post transplantation) from the human stem and progenitor cells is sustained by cotransplantation of human bone marrow stromal cells engineered to produce human IL-3 (huIL-3). Production of huIL-3, which is species-specific, in the mice has no discernable effect on murine hematopoiesis. 11 Reciprocally, human hematopoietic cells do not undergo long-term hematopoiesis in bnx mice in the absence of human IL-3. The bnx/hu xenograft model allows investigation of the impact of different ex vivo transduction protocols on both the efficiency of gene transfer into stem cells and the maintenance of pluripotentiality. 3, 4, 11, 12, [17] [18] [19] [20] [21] [22] In bnx mice, cultured CD34
+ cells from human bone marrow engraft to low levels (1-10% of the bone marrow replaced) and survive long-term. 11 From the transplanted human cells, all myeloid lineages, erythroid progenitors and T lymphocytes develop. The mature cells and clonogenic human hematopoietic progenitors have been recovered for as long as 18 months. However, no cells of the B lineage were detected from transplanted CD34 + and CD34 + /CD38 human cells to high levels, with up to 80% of the bone marrow replaced. [5] [6] [7] [8] [9] [10] [23] [24] [25] [26] [27] [28] [29] Cells of the B lineage are the most prevalent human hematopoietic population recovered from engrafted NOD/SCID mice. Myeloid cells, and erythroid and myeloid progenitors are also recovered, but human T cells are seldom generated. 5, 10, [23] [24] [25] [26] [27] [28] [29] Previously, we tested several possible explanations for the lack of human B lymphocyte differentiation in bnx mice, as opposed to NOD/SCID mice. We thought that the most probable cause for the lack of B cell development was the presence of co-transplanted primary stromal cells engineered to express human IL-3 in the bnx/hu xenograft system. Ball et al 30 have shown that IL-3 can impair B lymphopoiesis in the murine system. Since the presence of human IL-3 is necessary to allow sustained human hematopoiesis in bnx mice, 11 we could not test the potential for human progenitors to develop into B lymphocytes in its absence. We therefore tested secretion of the lymphoidspecific cytokine IL-7, in addition to reduced levels of IL-3 secreted from engineered stromal cells into the circulation of bnx mice. We hypothesized that IL-7 might override the effects of IL-3, to augment human B lymphopoiesis from co-transplanted human bone marrow-derived progenitors. However, although IL-7 was secreted at supraphysiological levels into the murine bloodstream for at least 6 months, only human T lymphocytes were detected in those mice, with a lack of human B lymphoid and myeloid development. 19 Another possibility was that the preculture period in cytokines used in our studies to transduce the CD34 + cells prior to transplantation could damage the potential for subsequent B lymphopoiesis. The 72 h in vitro exposure to IL-3 prior to transplantation, done to allow retrovirus-mediated transduction of a portion of the cells, might prevent subsequent B lymphopoiesis from the transplanted progenitor cells, as had been previously described in the murine system. 30, 31 We therefore did direct comparisons, by culturing human bone marrow derived CD34
+ progenitors with and without addition of IL-3 prior to transplantation. There was no significant difference in the levels of engraftment or lineage development in the groups of mice transplanted with human bone marrow progenitors cultured with and without IL-3. There was no development of human CD19
+ B lymphocytes in either group of mice, regardless of whether the transplanted cells had, or had not been exposed to IL-3 prior to transplantation. 3 The duration of culture of human hematopoietic progenitors might have been another important factor in determining the subsequent differentiative capacity. However, CD34
+ and CD34 + /CD38 − cells isolated from human bone marrow, transplanted after only 1 h in vitro, also failed to develop into B lymphocytes in bnx mice, though differentiation into the other hematopoietic lineages occurred to levels comparable to controls cultured with cytokines and stromal support for 72 h. 4 The microenvironment or cytokine content in the serum of bnx mice could be deficient in factors required by developing human B lymphocytes, whereas the necessary factors appear to be present in NOD/SCID mice. It was also possible that bnx mice produce an inhibitor of B lymphopoiesis that is not present in NOD/SCID mice. However, in the current studies, we have ruled out these possibilities, and show by direct comparison, that the lack of B lymphocyte development from human bone marrowderived hematopoietic progenitors in bnx mice can be largely attributed to the low B lymphocyte progenitor number and generative capacity contained in adult and pediatric bone marrow, as opposed to umbilical cord blood. The current studies demonstrate that the bnx/hu model of hematopoiesis can be used to study human B lymphocyte development, and have important implications for human umbilical cord blood vs bone marrow transplantation, since in the latter, B lymphopoiesis is often slow to recover. [14] [15] [16] [32] [33] [34] 
Materials and methods

Human progenitors
Normal human bone marrow cells were obtained from screens used to filter marrow during harvest of allogeneic donors, under a protocol approved by the Committee on Clinical Investigations (CCI) at Childrens Hospital, Los Angeles. Normal human umbilical cord blood samples were collected at Kaiser Permanente, (Los Angeles, CA, USA) also by approval of the CCI at Childrens Hospital Los Angeles. CD34
+ progenitors were isolated from ficolled mononuclear cell fractions from both sources by incubation with the monoclonal antibody HPCA-1 (Becton Dickinson, San Jose, CA, USA), followed by goat anti-mouse conjugated immunomagnetic beads (Dynal, Oslo, Norway).
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CD34
+ CD38 − cells were isolated from human marrow by pre-enrichment of CD34 + cells using MiniMACS columns (Miltenyi Biotec, Auburn, CA, USA), followed by labelling with fluorescein isothiocyanate (FITC)-CD34 (HPCA-2; Becton Dickinson Immunocytometry Systems (BDIS), San Jose, CA, USA) and phycoerythrin (PE)-CD38 (leu 17; BDIS). The CD34 + /CD38 − cells were then isolated by FACS acquisition using a stringent gate as described. 4 
+ and CD34 + /CD38 − cells from bone marrow and umbilical cord blood were transplanted 1 h after isolation, after 72 h on fibronectin (Retronectin, Takara Shuzo, Otsu, Japan), or after 1 and 2 weeks culture on irradiated monolayers of allogeneic stromal cells, as described.
35,36
Biochambers
Chambers were prepared by adhering 0.45 m HA type Millipore filters (13 mm) to both sides of a plastic ring with nontoxic MF cement No. 1 (Millipore Corporation, Bedford, MA, USA), as described. 37 The constructed chamber was sterilized by ethylene oxide. Each chamber was filled with 3 × 10 4 CD34 + stem cells from human bone marrow and 2 × 10 4 S17 stromal cells in 120 l of Isocove's modified Dulbecco's medium plus 20% FCS. After filling, each chamber was stoppered with a plastic rod and a drop of cement. The chambers were placed in 35 mm tissue culture dishes with 2 ml of medium and left overnight in the incubator at 37°C and 5% CO 2 , to test for sterility. One chamber per host animal was then implanted subcutaneously in the back of anesthetized 3-month-old bnx mice.
The chambers were removed from the mice 1 month after implantation. The adhering tissue and vasculature were carefully removed from the exterior of the chamber, then the contents of each chamber were collected and prepared for FACS analysis. The bone marrow and the spleen of the mice were also prepared for FACS analysis. Murine and human antibodies were used to analyze the contents as listed below. Other chambers were fixed in 2% glutaraldehyde and processed for immunohistochemistry by the Pathology Laboratory at Childrens Hospital of Los Angeles.
In vitro B lymphocyte progenitor assays
The murine stromal cell line S17 (generously given to Dr Crooks by Dr Kenneth Dorshkind, University of California at Los Angeles) was grown and plated in 96-well plates for the B lymphocyte progenitor assay as described. 36 Briefly, the assays were done by plating CD34 + /CD38 − cells onto S17 stroma in RPMI 1640 (Irvine Scientific, Santa Ana, CA, USA), 5% fetal calf serum (FCS; screened lots from BioWhittaker, Walkersville, MD, USA), 2-ME (50 mol/l, Sigma, St Louis, MO, USA), penicillin/streptomycin (Gemini Bioproducts, Calabasas, CA, USA), and l-glutamine (Gemini Bioproducts). The cloning efficiency of CD34 + /CD38 − cells from umbilical cord blood and bone marrow was determined by plating cells in limiting dilution assay and as single cells into each well of 96-well flat bottomed plates containing pre-established S17 stroma, using the Automated Cell Deposition Unit of the FacsVantage (Becton Dickinson (BDIS)). After a growth period of 2-4 weeks, clones containing more than 500 cells were scored as positive. The identity of the B lymphocytes was confirmed by staining for CD19 using the Leu 12 antibody (BDIS), followed by FACS analysis using the FacsVantage and Cellquest software (BDIS).
Mice
All studies used 6-week-old beige/nude/xid homozygous mice (bg.bg/nu.nu/xid.xid, NIH-3, Taconic Farms, Germantown, NY, USA) bred at CHLA. Co-transplantation of human progenitors and stromal cells producing IL-3 was performed as previously published, with sublethal conditioning done by injection of 150 g/kg 5-FU 48-72 h prior to injection of human marrow. 11 Mice were sacrificed by 90% CO 2 /10% O 2 narcosis, 6-18 months after transplantation with human cells. Bone marrow was flushed from the tibiae and femurs of each mouse into 1× phosphate buffered saline (PBS), dispersed with a fine needle, and used for the assays described below. The remainder of each bone marrow sample was viably cryopreserved for later analyses.
FACS analysis
Single cell suspensions from the marrow and spleen of cotransplanted mice were preincubated for 15 min on ice with unconjugated mouse immunoglobulin (MsIgG, Coulter, Hialeah, FL, USA). Directly conjugated antibodies used to identify human-specific cell surface antigens were: HLE-1 (anti-CD45, Becton Dickinson (BD)), My9-RD1 (anti-CD33, Coulter), Leu-12 (anti-CD19, BD), Leu 16 (anti-CD20, BD), Leu-3a (anti-CD4, BD), and Leu-2a (anti-CD8, BD). The anti-mouse CD45-R-PE antibody (Pharmingen, San Diego, CA, USA) was used to identify murine leukocytes. Following a 15 min antibody binding period on ice, samples were depleted of red blood cells by resuspension in Ortho Lysis Buffer (BD), washed, and fixed in 1% paraformaldehyde. Samples were acquired on a Becton Dickinson FACScan and analyzed using the Cellquest software package (BD). Ten thousand events were acquired for each sample. In all experiments, parallel staining and FACS analyses were done on normal human and non-transplanted bnx mouse bone marrow controls, to confirm that none of the human-specific antibodies cross-reacted with murine cells.
Statistical analyses
The significance of each set of values was assessed using the two-tailed t-test assuming equal variance with the Excel 5.0 software (Microsoft Corporation, Seattle, WA, USA). Average values are listed with standard deviations. The standard error of the mean was used in cases where all values were listed in table format.
Results
Engraftment of human hematopoietic cells in bnx mice
A major limitation of the bnx/hu xenograft system has been the absolute lack of development of human B lymphocytes in the mice, which has prevented analysis of the efficiency of gene transfer into human stem cells capable of trilineage B, T, and myeloid development using our previously described single-cell clonal integration analysis techniques. 17, 18, 22 Figure 1 shows an analysis of the total human CD45 + hematopoietic cell engraftment in 50 bnx mice transplanted with CD34 + or CD34 + /CD38 − cells from human bone marrow, and the lack of significant development of human CD19 + B lymphocytes in each of the mice. Nine of these mice were transplanted with CD34 + /CD38 − cells that had been cultured for only 1 h, and the remainder of the cell inocula had been cultured for 72 h prior to transplantation.
Co-transplantation of S17 stromal cells and B lymphocyte progenitors into bnx mice
We wanted to explore the possibility that mature human B lymphocytes might be selectively destroyed in bnx mice, while hematopoietic progenitors, myeloid cells, and T lymphocytes escaped rejection. There is no apparent killing of human B lymphocytes in the NOD/SCID xenograft system, but the mutations rendering the mice immunodeficient are very different. The possibility remained that bnx mice might be capable of rejection of certain human hematopoietic lineages. We therefore transplanted human B lymphocytes that had differentiated in vitro, as described, 36 from umbilical cord blood CD34 + progenitors on the S17 stromal cell line for 2 weeks. The adherent plus non-adherent fraction of each culture, containing CD19
+ B lymphocytes, 
/38
− progenitors from human bone marrow. The total human cell engraftment and B lymphocyte levels were assessed in 50 bnx mice, 4-12 months after co-transplantation of bone marrow-derived progenitor cells and IL-3 producing stromal cells. Nine of these mice were transplanted with CD34
− cells that had been cultured for only 1 h, and the remainder of the cell inocula had been cultured for 72 h prior to transplantation. Marrow cells from each mouse were labelled with anti-CD45, a panspecific human leukocyte marker, and anti-CD19, which identifies human B lymphocytes. The levels of each phenotype, obtained by FACS analysis, are shown in direct comparison. Figure 2 Human B lymphocytes are not specifically rejected by bnx mice. Cultures containing unirradiated S17 stroma and human umbilical cord blood progenitors were injected i.v. into bnx mice, following 2 weeks of growth and differentiation toward the B lymphocyte lineage in vitro. The mice were killed and their marrow was analyzed 1 month later. Human CD19 + cells could be detected in the bnx marrow, as shown on the left, demonstrating that the human B lymphocytes that had developed in vitro had not been specifically rejected. The bone marrow from an age-matched non-transplanted bnx mouse, labelled with the same monoclonal antibodies, is shown on the right for comparison. undifferentiated progenitors, and nonirradiated S17 stromal cells, was transplanted into cohorts of bnx mice. This approach was designed to determine whether committed B lymphocyte progenitors and mature cells could engraft and survive in bnx mice, and potentially to develop a model to allow B lymphocyte differentiation in bnx mice in a manner similar to what occurs in vitro. 38 Our findings from this experiment were three-fold. First, the mature human B lymphocytes were not destroyed or rejected by the bnx mice. Human CD19
+ cells were detected in the mice 1 month after transplantation ((n = 10), Figure 2 ). The second finding was that the S17 stromal cells caused a significant elevation in the levels of murine B220+ and surface IgM+ B lymphocytes, in comparison to the levels obtained from control mice transplanted with human IL-3 producing stroma ( Table 1 ). The control mice had levels of murine B220+ B lymphocytes, and other hematopoietic lineages that were equivalent to the levels obtained in nontransplanted animals. We had previously determined that the presence of human IL-3 in the bnx circulation has no discernable effect on murine hematopoiesis. 11 The numbers of NK cells and T lymphocytes were not increased by the presence of the S17 stromal cells ( Table 1 ). The final, and rather disappointing, result from this study was that the unirradiated S17 cells, which are immortalized, formed solid tumors in the mice. Since bnx mice have no immune system, and lack NK cell function due to the beige mutation, 39 this result was not surprising. These studies 0.01 ---control Bone marrow was recovered from bnx mice 1-6 months after co-transplantation of human hematopoietic progenitors and normal human stromal cells engineered to secrete human IL-3 (NH stroma) or the S17 murine stromal cell line as described. The percentages of murine cells of the B and T lymphoid, NK, and granulocytic lineages were determined by FACS analysis, after staining with rat anti-mouse monoclonal antibodies (anti-B220, IgM, CD3, NK1.1, and GR-1, respectively). The percentages of the ungated murine bone marrow cells that were positive for each lineage marker are shown.
demonstrated that the S17 line, known to promote human B lymphocyte differentiation, could not be used for in vivo studies, unless cell growth was controlled in some way. However, the studies established that human B lymphocytes could engraft and survive in bnx mice.
Implantation of human progenitor cells and S17 stroma into bnx mice in biochambers
We had determined in previous studies that irradiated cells were rapidly cleared after transplantation into bnx mice.
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While a portion of the irradiated cells survived for 1 month in vitro, they were undetectable in vivo after 7 days. These data suggest that there is a mechanism by which irradiated, damaged cells are recognized and removed, even in immune deficient mice. The clearance might be done through the macrophage and reticuloendothelial pathway, which is relatively normal in bnx mice, in contrast to the lymphoid system. Therefore, we did not attempt to transplant irrradiated S17 cells into the mice, to provide a temporary stimulus to support B lymphocyte differentiation, without the risk of tumor formation. Rather, we turned to an alternative approach, whereby we introduced the S17 cells into the mice, confined inside biochambers with the human hematopoietic progenitor cells. The S17 cells should not be able to form tumors, metastasize, and kill the mice, if confined within the chambers.
We constructed biochambers containing S17 stroma and human CD34
+ cells isolated from normal human bone marrow, using a modification of the techniques previously described by Andrades et al. 40, 41 The chambers were implanted subcutaneously into the backs of individual mice. Paired chambers were removed 1 month later and fixed for histological analysis, or opened and dissected for FACS, cytospin slide preparation, and immunohistochemistry. Human B lymphocyte development was not observed within the chambers, although the stromal cells were maintained, and some myeloid development was observed. The S17 stroma remained healthy within the chambers, and could be recultured upon removal of the chambers from the mice. The S17 cells continued to secrete B lymphocytestimulatory factors into the murine circulation from within the biochambers, which resulted in an elevation in the levels of murine B220+ B lymphocytes in the bnx bone marrow and spleen, as compared to control mice, as we had previously observed with the direct S17 intravenous transplantation (Table 1) .
In vitro studies: determination of B lymphocyte progenitor number in human bone marrow vs umbilical cord blood
We were intrigued by the fact that human bone marrow derived progenitors did not form B lymphocytes in the biochambers implanted into bnx mice, because we had ruled out immediate rejection, and had provided the progenitors with an environment known to strongly promote human B lymphocyte differentiation, with no success. Two possibilities remained: either there was a factor in the bnx serum that inhibited B lymphocyte differentiation (and had diffused into the biochambers), or else insufficient cells with B lymphoid potential had been used in our transplantation and biochamber experiments, in contrast to the experiments where the entire S17 cultures were transplanted. The biochamber experiments used human bone marrow-derived CD34 + progenitors, while the S17 culture transplantation experiments used human umbilical cord blood-derived CD34 + progenitors. In the majority of the published NOD/SCID transplantation experiments, the mice had been transplanted with human umbilical cord blood progenitors, and excellent B lymphocyte development had resulted. 1, 2, 8, [26] [27] [28] Our previous experiments in bnx mice had exclusively used mobilized peripheral blood or bone marrow-derived progenitors, except in the case of direct transplantation of the S17/ B lymphocyte progenitor cultures, in which umbilical cord blood progenitors had been used. In the latter experiments, human CD19 + B lymphocytes had been recovered from the bnx bone marrow. Based upon these results, we hypothesized that the number and/or growth capacity of stem and progenitor cells with the potential to form B lymphocytes was significantly lower in human bone marrow than in umbilical cord blood. To examine this possibility, we initially did in vitro experiments to quantitate the number of progenitors with B lymphopoietic capacity in human bone marrow vs umbilical cord blood samples. CD34 + /CD38 − cells are a primitive, quiescent population that has been demonstrated to contain lymphomyeloid repopulating cells. 4, 42 This cell population lacks the more mature, differentiated hematopoietic progenitors that are contained within the bulk CD34 + population. 36, 38, 43, 44 We isolated CD34
+ /CD38 − cells from normal human bone marrow donors to determine the frequency of progenitors with B lymphopoietic capacity. CD34
+ /CD38 − cells were deposited into individual wells of a 96-well plate that had been precoated with S17 stromal cells, in medium previously determined to promote B lymphocyte development. 36, 38 The average B lymphocyte progenitor cloning efficiency in the umbilical cord blood samples, as we have previously reported, was 3.02 ± 0.67% (n = 6, Ref. 36) . In contrast, the cloning efficiency from normal human bone marrow, in the current studies, was only 0.057 ± 0.04% (n = 5). In addition, each B lymphocyte progenitor that grew from bone marrow in the clonal assay produced at least 100-fold fewer CD19
+ cells as each clone that grew in the same assay from umbilical cord blood. These data suggest that both quantitative and qualitative differences exist between marrow and CB-derived B progenitors.
If the in vitro studies correlate with the efficiency of B lymphopoiesis in vivo, we had been transplanting very few marrow-derived progenitors that had B lymphopoietic capacity into each bnx mouse. The total number of CD34 + /CD38 − cells transplanted into each mouse, from bone marrow or umbilical cord blood, was 2000. When taking the B lymphopoietic cloning efficiency into consideration, 2000 CD34 + /CD38 − UCB progenitors would contain 60.4 stem or progenitors capable of giving rise to B lymphocyte progeny. In contrast, 2000 CD34 + /CD38 − bone marrow progenitors would only contain 1.1 cells with B lymphopoietic capacity (calculated as: 2000 cells × percent cloning efficiency = number of B precursors injected). This discrepancy could explain the lack of B lymphocyte development from bone marrow in bnx mice. To test this hypothesis directly, transplantation of equivalent numbers of umbilical cord blood and bone marrow progenitors into sibling bnx mice was compared.
Transplantation of human bone marrow vs umbilical cord blood into bnx mice: comparison of B lymphocyte generation
To extend the in vitro results into in vivo experiments, we transplanted 2000 CD34 + /CD38 − cells from either bone marrow or umbilical cord blood into bnx mice, and determined the capacity for human B lymphocyte formation following long-term engraftment (6-18 months). Prior to transplantation, as in our previous studies, the cells from both BM and UCB were subjected to 72 h in culture to allow retroviral marking of a portion of the cells. In one study, the progenitor cells from umbilical cord blood were cultured for 2-3 weeks on human stromal cells prior to transplantation.
The results of the transplantation experiments are shown in Figure 3 and in Table 2 . There was almost no development of human B lymphocytes from human bone marrow derived progenitors transplanted into the mice. The average percentage of human CD19 + B lymphocytes in the bone marrow group was 0.02 ± 0.01 (n = 18). In contrast, the percentage of human CD19 + B lymphocytes in mice transplanted with progenitors isolated from UCB was 1.3 ± 0.2 (n = 29), a significant increase (P = 0.0000001). The B lymphocytes in mice transplanted with human umbilical cord blood progenitors comprised an average of 16.7 ± 1.2% of the human graft, as determined by reactivity with an antibody to human CD45, a pan-leukocyte marker ( Table 2) . Human B lymphocytes developed to similar percentages of the total human graft in mice transplanted with human cord blood progenitors that had been cultured for 72 h (mice 31-47, Table 2 ) or for 2-3 weeks prior to transplantation (mice 19-30, Table 2 ). The averages, comparing the two groups, were 19.3 ± 2.1 (n = 12) vs 14.8 ± 1.3 (n = 17) percent of the total human graft, respectively.
Transplantation of UCB and BM from the same donor
In a final study, we were able to obtain both umbilical cord blood and bone marrow samples from the same donor, a patient with X-linked severe combined immunodeficiency (X-SCID), which severely affects development of the T lymphoid lineage, but allows generation of B lymphocytes. Details on this patient are discussed elsewhere (Nolta et al, submitted) . Equivalent numbers of CD34 + progenitors from the patients UCB and BM were cultured ex vivo for 72 h in identical conditions; in the presence of 10% fetal calf serum, the fibronectin fragment Retronectin (Takara Shuzo, Otsu, Japan), IL-3, IL-6, SCF, and FL. Cells were transplanted into bnx mice and allowed to engraft and maintain human hematopoiesis for 12 months. At the end of the engraftment period, the percentage of human CD19 + B lymphocytes in the marrow of the bnx mice was determined by FACS. In accordance with our previous studies, human B lymphocyte development had occurred in mice transplanted with umbilical cord blood, but not bone marrow. The average percentage of human CD19
+ cells in the marrow of mice transplanted with UCB was 1.0 ± 0.2%, and comprised an average of 23% of the total human graft (Table 3 ). In contrast, no human B lymphocytes were recovered from mice transplanted with marrow progenitors from the same donor (Table 3) . Therefore, development of B lymphocytes from the umbilical cord blood, but not bone marrow from the same donor ruled out the possibility that the results described in the previous section had been caused by patient-to-patient variability. These data confirm that on a per cell basis, the capacity for human B lymphopoiesis, in the bnx/hu xenograft model, is higher in umbilical cord blood than in bone marrow.
Discussion
Robust development of B lymphocytes from transplanted human progenitor cells occurs in NOD/SCID mice. [5] [6] [7] In sharp contrast, no B lymphocyte development had been + B lymphocytes in bnx BM 6-18 months after transplantation is significantly higher in mice transplanted with human hematopoietic progenitors isolated from UCB, as compared to BM. The data were obtained by labelling long-term engrafted bnx bone marrow cells with monoclonal antibodies specific for human CD19, followed by FACS analysis. Eighteen mice were analyzed following transplantation with bone marrow-derived CD34
+ and CD34 detected from human CD34 + progenitors in the bnx/hu xenograft system (prior to this report), in 372 mice tested, although myeloid and erythroid progenitors, ␣␤ TCR + T lymphocytes, and all lineages of mature myeloid cells were recovered. 3, 4, 11, 12, [17] [18] [19] [20] 22 The duration of human cell engraftment in the prior bnx/hu studies ranged from 2 to 12 months, with a mean of 8 months. Whereas NOD/SCID mice are a highly permissive system for human B lymphocyte development, bnx mice appeared to be a rather stringent one. The current studies have examined the cause of this apparent discrepancy, and have determined that the major reason that B lymphocyte development was not previously observed in the bnx/hu xenograft model was that the bnx mice were exclusively transplanted with human bone marrow-derived progenitors, whereas in the NOD/SCID xenograft systems, umbilical cord blood was the major source of the transplanted progenitors. The current studies demonstrate that the capacity for both in vitro and in vivo B lymphopoiesis is much higher in umbilical cord blood than in bone marrow progenitor samples containing an equivalent number of cells.
There are several factors which could have contributed to the lack of human B lymphocyte development in bnx mice, that were ruled out in the current and past studies. In the bnx/hu system, human IL-3 must be supplied to allow long-term engraftment of human cells. The presence of supraphysiological levels of IL-3 in the mice could reduce the extent of B lymphocyte development, if the human system parallels what is seen in the murine system. 30, 31 However, human IL-3 has been supplied to SCID mice throughout the engraftment period without reducing the extent of human B lymphocyte development. 8 The presence of supraphysiological levels of human IL-3 in the medium that the cells were cultured in prior to transplantation in the bnx/hu xenograft system could also have had adverse affects on human B lymphopoiesis. In the current studies, however, we determined that human B lymphocytes can, in fact, develop from hematopoietic stem and progenitor cells that have been exposed to high concentrations of IL-3. Cells were cultured for a minimum of 72 h in 10 ng/ml IL-3 in vitro prior to transplantation, and then were exposed to systemic levels averaging 24 pg/ml in vivo. 11 Human CD34 + and CD34 + /38 − progenitors from umbilical cord blood, but not adult or pediatric bone marrow, gave rise to CD19 + B lymphocyte progeny averaging 17% of the human graft, in the presence of IL-3.
The development of human cells could also be altered by factors other than IL-3, during ex vivo culture or handling of the cells prior to transplantation. Components of the fetal calf serum, or differences in adhesive interactions during culture could alter the capacity of the cells to home or differentiate normally after transplantation. 12, 21 In the bnx/hu model, the human cells are transduced and cultured for a minimum of 72 h prior to transplantation. In contrast, cells injected into NOD/SCID mice in many studies have been freshly isolated or co-cultivated on a layer of irradiated murine fibroblasts. However, as we had determined (Figure 1) , and in prior studies, 4 that human hematopoietic progenitors from bone marrow, cultured for only 1 h, did not give rise to B lymphocytes in bnx mice, it seemed that the duration of culture was a less critical factor than the total B lymphocyte progenitor count. The distinct possibility remains, however, that there are substantial differences in the NOD/SCID and bnx mouse models. In contrast to the data presented here, bone marrow progenitors can give rise to B lymphocytes in NOD/SCID mice. 45 Therefore, the NOD/SCID microenvironment might provide a more permissive microenvironment for B lymphocyte development than does the bnx microenvironment.
The human B lymphocytes that developed in mice transplanted with umbilical cord blood progenitors, in the current studies, did not exceed an average of 25% of the total Bone marrow was recovered from bnx mice 6-18 months after co-transplantation of bone marrow (BM) or cord blood (CB)-derived human CD34 + cells and IL-3 producing stromal cells. The percentages of human CD45 + (panspecific human leukocyte) and lineage-specific cells in the BM were determined by FACS analysis. The percentages of the ungated bone marrow cells that were positive for each human-specific lineage marker are shown. Normal human marrow and age-matched, non-transplanted bnx mice were analyzed concurrently to verify the species specificity of the monoclonal antibodies. human graft. In contrast, B lymphocytes can comprise the majority of the human hematopoietic cell graft, in NOD/SCID mice. The most scientifically interesting reason for preferential generation of different lineages of human cells in NOD/SCID and bnx mice would be that there are differences in the microenvironment or circulating cytokines in the two strains which influence the differentiation of human hematopoietic cells. It is plausible that, in the NOD/scid strain, factors that support human B lymphopoiesis could be elevated. The differences in lineage development from human hematopoietic cells transplanted into the NOD/SCID vs bnx mice are extremely interesting, and should be characterized in direct comparisons. Transplantation of the same population of human hematopoietic progenitors into both strains, maintained at the same facility, will further define the differences in the xenograft models.
From the current studies, we conclude that one of the major sources of variability to explain the differences in the human B lymphocyte levels that develop in NOD/SCID vs bnx mice is the tissue origin of the transplanted cells. Usually, in the NOD/SCID model, cord blood progenitors have been transplanted, [5] [6] [7] whereas studies in bnx mice to date have been primarily conducted with bone marrow derived CD34 + cells. 3, 4, 11, 12, [17] [18] [19] [20] 22, 46 In the current studies, we examined the potential for B lymphocyte development from transplanted human bone marrow and umbilical cord blood progenitors in bnx mice. Based on these studies, we attribute the difference between B lymphocyte levels in bnx mice following transplantation with UBC and BM to the fact that precursor cells with both in vitro cloning and in vivo reconstituting B lymphocyte potential are present in adult and pediatric bone marrow samples at levels that are significantly lower than in umbilical cord blood.
Transplantation of umbilical cord blood in place of bone marrow or mobilized peripheral blood stem cells has been used successfully in recipients with low body weight, so that the number of stem cells per kilogram transplanted is not compromised. 47, 48 Umbilical cord blood progenitor and stem cells have been demonstrated to have an extensive capacity for expansion and repopulation. 4, 7, 10, 24, 26, 28, 43, 49, 50 The current studies highlight another important aspect of umbilical cord blood transplantation: that UCB contains a higher percentage of progenitor cells with in vitro and in vivo B lymphocyte reconstituting capacity, as compared to adult and pediatric bone marrow. This is an important consideration, because following mobilized peripheral blood stem cell or bone marrow transplantation, B lymphocyte function can take months to years to attain relatively normal levels, and remains defective in some patients. 33 Kiesel et al 32 analyzed 22 autografted patients, from 1 to 34 months post transplantation, and found that only five had normal B lymphocyte proliferative responses in all tests. Small et al 34 assessed B lymphocyte reconstitution in 88 recipients of autologous, conventional, or T-depleted bone marrow transplantation. They determined that B lymphocyte levels in the circulation returned to normal 4 months post transplantation, and that the B lymphocyte development post transplantation recapitulated normal B lymphocyte ontogeny. In early stages post transplantation, the B cell function more closely resembled that of umbilical cord blood, than mature human peripheral blood. It has also been previously demonstrated that B lymphoid progenitors with an immature phenotype are more common in fetal than adult bone marrow. 51 These studies, combined with the current investigation into the relative numbers of engrafting cells with the potential for B lymphocyte development, indicate that umbilical cord blood might lead to enhanced reconstitution of the B lymphocyte compartment following transplantation into human, as well as murine recipients.
